NCT07401355Not yet recruiting
Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
This trial is a monocentric, clinico-biological cohort study with prospective enrollment, aiming to develop a method for detecting and sorting CTCs (circulating tumour cells) from liquid biopsies (fresh blood samples) in patients with advanced or metastatic soft tissue sarcomas.This study include collection of clinical data, of tumor samples (collected during standard of care).
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 31 Jan 2030
- Lead sponsor
- Centre Leon Berard
- Diseases
- Sarcoma
- NCT number
- NCT07401355
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Mar 2026 to the primary completion date, 31 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results;
- Prior treatment with anthracycline;
Other illness
- History of other malignancy other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of disease for at least 3 years;
- Metabolic syndrome;
Other
- Pregnant or breast-feeding woman criteria
Who the study is looking for
- Male or female patients ≥ 18 years at the day of consenting;
- Histologically confirmed diagnosis of Soft Tissue Sarcoma (STS) excepted GIST.
- Metastatic disease or unresectable locally advanced malignancy for which standard therapy by anthracycline is decided;
- At least one measurable lesion as per RECIST version 1.1.;
- ECOG Performance Status of 0-2;
- Patients must have an adequate organ and bone marrow function at baseline;
- Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with procedures as per protocol;
- Covered by a medical insurance.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BRAHMI Mehdi Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.